Denaverine is an antispasmodic drug. It was developed in Germany and patented in 1974. Denaverine hydrochloride is used in veterinary medicine under the trade name Sensiblex as a muscle relaxant for the myometrium of cows and dogs during parturition. Technically, the active moiety is supplied as the hydrochloride salt to improve aqueous solubility and handling; the API is typically a white to off white crystalline powder, characterized by melting point range, specific optical rotation and spectroscopic fingerprints (IR, 1H and 13C NMR, and MS) for identity confirmation. The compound produces direct spasmolytic effects on smooth muscle and is characterized in technical dossiers by an HPLC assay for potency, related-substance profiling, water content by Karl Fischer, residual solvent analysis by GC, and elemental impurity limits consistent with ICH guidance. Standard manufacturing controls include validated synthetic route intermediates monitoring, in-process checks for solvent removal, and stability testing under ICH conditions to define retest or shelf life.
Parent: Denaverine
Parent: Denaverine
Parent: Denaverine
Typical commercial specifications for denaverine hydrochloride reference high purity and tight control of related substances; a representative technical specification is assay by HPLC not less than 98.0 percent w/w, individual related substances controlled to not greater than 0.2 to 0.5 percent each depending on qualification status, and total unspecified impurities controlled to not greater than 1.0 to 1.5 percent, with water content typically below 0.5 percent w/w and residual solvents set per ICH Q3C limits. Common related compounds observed during synthesis and degradation studies include dealkylated analogs, desmethyl impurities, N-oxide species, benzyl or aryl side-chain derivatives and positional isomers; these are generally observed in the range of 0.01 to 0.5 percent for individual impurities under normal process control and can be higher in unrefined intermediates. Control strategy relies on a stability indicating HPLC method with orthogonal confirmation by MS, and qualification thresholds follow ICH Q3A and Q3B principles for identification and toxicological qualification.
Denaverine is used as an antispasmodic agent to relax smooth muscle; its veterinary use includes denaverine hydrochloride (Sensiblex) as a myometrial muscle relaxant for cows and dogs during parturition, and in technical contexts it is applied where transient uterine relaxation or relief of smooth muscle spasm is required.
Typical technical specifications set assay by validated HPLC at not less than 98.0 percent w/w, individual related substances commonly limited to 0.2 to 0.5 percent each, total impurities to 1.0 to 1.5 percent, water below 0.5 percent w/w and residual solvents controlled per ICH Q3C; exact limits depend on product grade and regulatory filing.
Impurities are detected and quantified primarily by a stability indicating HPLC method with UV detection, supported by LC-MS for peak identification, GC for volatile residual solvents, Karl Fischer titration for water, and ICP-MS or AAS for elemental impurities; methods are validated for specificity, accuracy, precision, linearity and robustness.
Denaverine hydrochloride should be stored in tight containers protected from moisture and light, at controlled room temperature or per stability data, handled with standard laboratory PPE, and sampled and packaged to prevent contamination and limit exposure to elevated temperature or humidity.
